المؤلفون: Bartko TM; Labcorp Early Development Laboratories Inc., Madison, WI, United States of America. Electronic address: theresa.bartko@labcorp.com., Lutgen SM; Labcorp Early Development Laboratories Inc., Madison, WI, United States of America., Ross RA; Labcorp Early Development Laboratories Inc., Madison, WI, United States of America., Walisser JA; Labcorp Early Development Laboratories Inc., Madison, WI, United States of America., Garske EP; Labcorp Early Development Laboratories Inc., Madison, WI, United States of America., Kopelke KR; Labcorp Early Development Laboratories Inc., Madison, WI, United States of America., Ashcroft-Hawley K; Labcorp Early Development Laboratories Ltd., Harrogate, UK., Tang HM; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States of America., Kremer JJ; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States of America., Friedrichs GS; Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States of America., Nichols JV; Labcorp Early Development Laboratories Inc., Madison, WI, United States of America.

المصدر: Journal of pharmacological and toxicological methods [J Pharmacol Toxicol Methods] 2024 Jul-Aug; Vol. 128, pp. 107527. Date of Electronic Publication: 2024 Jun 08.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 9206091 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-488X (Electronic) Linking ISSN: 10568719 NLM ISO Abbreviation: J Pharmacol Toxicol Methods Subsets: MEDLINE

مواضيع طبية MeSH: Moxifloxacin*/administration & dosage , Moxifloxacin*/pharmacology , Amiodarone*/administration & dosage , Amiodarone*/pharmacology , Electrocardiography*/drug effects , Electrocardiography*/methods , Torsades de Pointes*/chemically induced , Long QT Syndrome*/chemically induced , Long QT Syndrome*/physiopathology, Animals ; Dogs ; Male ; Ether-A-Go-Go Potassium Channels/antagonists & inhibitors ; Ether-A-Go-Go Potassium Channels/metabolism ; Female ; Macaca fascicularis ; Fluoroquinolones/administration & dosage ; Fluoroquinolones/pharmacology ; Heart Rate/drug effects ; Potassium Channel Blockers/administration & dosage ; Potassium Channel Blockers/pharmacology ; ERG1 Potassium Channel/antagonists & inhibitors ; ERG1 Potassium Channel/metabolism